Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg

March 20, 2023

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg

March 14, 2023

Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for U.S. FDA Approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg

March 9, 2023

Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

February 27, 2023

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

January 10, 2023

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

March 20, 2023
Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg

March 14, 2023
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg

March 9, 2023
Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for U.S. FDA Approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg

February 27, 2023
Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

January 10, 2023
Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE